Floatz logo

kn046

Metastatic Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltdmonoclonal_antibodyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Capivasertib
Maryam Lustberg
Phase 3BB
Alisertib
Puma Biotechnology, Inc.
Phase 2BB
Trastuzumab Emtansine
Genentech, Inc.
Phase 2BB
Bp-C1
Meabco A/S
Phase 2BB

View all 50 →

Same molecule, other indications

kn046 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
squamous cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →